Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 930, for treatment of non-solid tumor malignancies stemming from Epstein-Barr Virus (EBV).

Read more at globenewswire.com